Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02434757
• Other study ID #: ACT1
• Status: Recruiting
• Phase: N/A
• First received: April 30, 2015
• Last updated: April 30, 2015
• Start date: February 2014
• Est. completion date: November 2015

Study information

• Verified date: September 2014
• Source: Phase III Clinical Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This small study is to investigate the efficacy and safety of Acthar as an adjunct therapy in patients with active rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARDs) and at least 3 biologic agents. An in adequate response is defined as having ≥ 6 tender joints, ≥ 6 swollen joints, plus C-Reactive Protein (CRP) levels and/or erythrocyte sedimentation rate (ESR) of ≥ 1.2 times the upper limit of normal in spite of aggressive treatment, including ≥ 7.5 mg/d prednisone. This will be a 20 week, prospective, multicenter, open-label study conducted at 3-4 university/medical centers and private practice settings in the US. A total of 20 eligible patients will be enrolled and other standard RA therapeutic agents, such as Methotrexate, DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), pain medications and others will not be discontinued. The primary endpoint will be the percentage of patients with reduction of ≥1.2 points of the Disease Activity Score in 28 joints (DAS-28) score.

Description:

>

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: November 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age at the time of participation

• Have a confirmed diagnosis of RA based on the 2010 ACR/EULAR criteria

• Currently on aggressive treatment with an inadequate response or AE to stable dose of DMARDs and biologic agents for 3 months prior to screening, and stable doses of NSAIDs, prednisone or equivalent dose of corticosteroid (dose =7.5 mg/d), and analgesics for 28 days prior to screening. Have active RA, defined as =6 swollen joints, =6 tender joints, plus CRP levels an /or an ESR =1.2 the upper limit of normal

• RA for art least 24 months and receiving maximum tolerated doses of at lease 3 biologic agents (at least 1 of which is anti-TNF-a) for 3 months

• Tuberculosis has not occurred within the recent past, as proven by a conventional x-ray, negative tuberculosis shin test (PPD), or quantiferon gold

Exclusion Criteria:

• Presence of any condition which could confound interpretation of the data, such as inflammatory arthritis (eg. psoriatic arthritis, gout or pseudogout)

• Presence of systemic fungal infections, recent surgery (within prior 3 months), or active ulcer disease (within the past 5 years)

• Current symptoms of severe, progressive, or uncontrolled renal, hepatic ,hematologic, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease

• Have had in last three months or planning to receive live or live attenuated vaccines

• Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in the study such as uncontrolled diabetes or hypertension

• History of or presence of active or latent tuberculosis (TB) based on QuantiFERON-TB gold test. Patients will be allowed in the study after receiving adequate treatment for TB

• Sensitivity to proteins of porcine origin

• History of cancer within the last 5 years, excluding basal cell carcinoma

• Glomerular filtration rate <30 mL/min -

• Uncontrolled diabetes mellitus

• Pregnant of lactating female patients. Each site to administer a pregnancy test to any female of childbearing potential before prescribing Acthar Gel. Only females with negative pregnancy test results are eligible. All sexually active males and females of childbearing potential must agree to use an adequate method of contraception throughout the period of the study.

• The following physical and laboratory test findings

• Patients with positive hepatitis B surface antigen

• Patients with positive hepatitis C antibody, who are also positive by recombinant immunoblot assay (RIBA) or by polymerase chain reaction (PCR)

• Hemoglobin level <8.5. g/dL

• White blood cell count <3000/mm (3 x 10/L)

• Serum Creatinine level >2 times upper limit of normal

• Serum alanine aminotransferase (ALT) or asparate amino- transferase (AST) >2 times upper limit of normal

• Any other laboratory test results that, in the opinion of the investigator might placed the patient at unacceptable risk for participation in this study

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• H.P. Acthar Gel
Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week

Locations

Country	Name	City	State
United States	Phase III Clinical Research	Fall River	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Ronald J. Rapoport, MD	Mallinckrodt

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with reduction of >1.2 points in DAS-28 score		After 12 weeks	No
Primary	20%, 50%, 70% Improvement based on American College of Rheumatology Criteria		After 12 weeks	No
Secondary	Improvement (decrease) in Vectra Disease Activity score		After 12 weeks	No
Secondary	Improvement (decrease) in Health Assessment Questionnaire		After 12 weeks	No
Secondary	Improvement in Functional Assessment of Chronic Illness Therapy Health Related Quality of Life Score		After 12 weeks	No